Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis

• US 20090069638A1
• Filed: 12/04/2006
• Published: 03/12/2009
• Est. Priority Date: 12/02/2005
• Status: Abandoned Application

• Current Assignee: Howard Murad
• Original Assignee: Howard Murad
• Inventors: Murad, Howard
• Application Number:
  US12/085,906
• Publication Number:
  US 20090069638A1
• Time in Patent Office: Days
• US Class Current: 600/300
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for achieving and maintaining an optimized cellular water homeostasis and good connective tissue health in humans, where cellular water homeostasis is expressed as the ratio of intercellular water (“ICW”) content to extracellular water (“ECW”) content homeostasis comprising the steps of (i) taking a first set of measurements of two or more of ICW, ECW and total body water (“TBW”) contend; (ii) comparing the first set of measurements against a predetermined set of values associated with a population of people; (iii) administering an initial dosing of a first composition comprising a therapeutically-effective amount of an amino acid/phospholipid pairing (“AAPP”); (iv) taking a follow-up set of measurements of two or more of TBW, ICW and/or ECW after the initial dosing; (v) comparing the follow-up set of measurements against the predetermined set of population values; (vi) administering a follow-up dosing of a follow-up composition comprising a therapeutically-effective amount of an AAPP; (vii) repeating steps (iv) through (vi) until the desired values of TBW, ICW and/or ECW are achieved.

Claims

1. A method for achieving and maintaining an optimized ICW/ECW homeostasis and good connective tissue health in humans comprising the steps of (i) taking a first set of measurements of two or more of TBW, ICW and/or ECW;

(ii) comparing the first set of measurements against a predetermined set of values associated with a population of people;

(iii) administering an initial dosing of a first composition comprising a therapeutically-effective amount of an amino acid/phospholipid pairing (“

AAPP”

);

(iv) taking a follow-up set of measurements of two or more of TBW, ICW and/or ECW after the initial dosing;

(v) comparing the follow-up set of measurements against the predetermined set of population values;

(vi) administering a follow-up dosing of a follow-up composition comprising a therapeutically-effective amount of an AAPP;

(vii) repeating steps (iv) through (vi) until the desired values of TBW, ICW and/or ECW are achieved.

2. The method of claim 1 wherein the initial dosing comprises an AAPP and at least one of an antioxidant, an anti-inflammatory agent, an essential fatty acid, a glycosaminoglycan, a trace mineral or a vitamin.

24. The method of claim 1 wherein the follow-up dosing comprises an AAPP and at least one of an antioxidant, an anti-inflammatory agent, an essential fatty acid, a glycosaminoglycan, a trace mineral or a vitamin.

46. The method of claim 1 wherein the AAPP in the initial dosing comprises an amino acid selected from the group consisting of phenylalanine, valine, tryptophan, tyrosine, isoleucine, methionine, histidine, alanine, leucine, lysine, proline, cysteine, glycine and glutamic acid.

50. The method of claim 1 wherein the AAPP in the initial dosing comprises a phospholipid selected from the group of lecithin and phosphatidylcholine.

51. The method of claim 50 wherein the AAPP in the initial dosing further comprises choline.

56. The method of claim 1 wherein the AAPP in the follow-up dosing comprises an amino acid selected from the group consisting of phenylalanine, valine, tryptophan, tyrosine, isoleucine, methionine, histidine, alanine, leucine, lysine, proline, cysteine, glycine and glutamic acid.

60. The method of claim 1 wherein the AAPP in the follow-up dosing comprises a phospholipid selected from the group of lecithin and phosphatidylcholine.

61. The method of claim 60 wherein the AAPP in the follow-up dosing further comprises choline.

66. The method of claim 2 where the essential fatty acid is an unsaturated C₁₈ fatty acid.

67. The method of claim 66 where the essential fatty acid is selected from the group consisting of octadecenoic acids, octadecadienoic acids and octadecatrienoic acids.

68. The method of claim 67 where the essential fatty acid is selected from the group consisting of 9-octadecenoic acid;

cis-cis-9,12-octadecadienoic acid;

all-cis-9,12,15-octadecatrienoic acid; and

all-cis-6,9,12-octadecatrienoic acid.

69. The method of claim 24 where the essential fatty acid is an unsaturated C₁₈ fatty acid.

72. The method of claim 2 wherein the initial dosing comprises an AAPP and at least one glycosaminoglycan and the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin, as well as their pharmaceutically acceptable salts and esters.

73. The method of claim 1 where the initial dosing comprises an AAPP and glucosamine.

74. The method of claim 73 where the glucosamine is n-acetyl glucosamine.

75. The method of claim 24 where the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin, as well as their pharmaceutically acceptable salts and esters.

76. The method of claim 1 where the follow-up dosing comprises an AAPP and glucosamine.

77. The method of claim 76 where the glucosamine is n-acetyl glucosamine.

78. The method of claim 1 where according to the first set of measurements ICW is below average and the initial dosing comprises an AAPP and at least one essential fatty acid.

79. The method of claim 1 where according to the follow-up set of measurements ICW is below average and (i) the initial dosing comprises an AAPP and at least one essential fatty acid and the follow-up dosing comprises an amount of essential fatty acid greater than the amount in the initial dosing or (ii) the initial dosing does not contain an essential fatty acid and the follow-up dosing comprises at least one essential fatty acid.

80. The method of claim 1 where according to the first set of measurements ECW is below average and the initial dosing comprises an AAPP and at least one glycosaminoglycan.

81. The method of claim 1 where according to the follow-up set of measurements ECW is below average and (i) the initial dosing comprises an AAPP and at least one glycosaminoglycan and the follow-up dosing comprises an amount of glycosaminoglycan greater than the amount in the initial dosing or (ii) the initial dosing does not contain a glycosaminoglycan and the follow-up dosing comprises at least one glycosaminoglycan.

82. The method of claim 1 where the desired level of TBW is average.

83. The method of claim 1 where the desired level of TBW is above average.

84. The method of claim 1 where the desired level of ICW is average.

85. The method of claim 1 where the desired level of ICW is above average.

86. The method of claim 1 where TBW, ICW and/or ECW are measured by a licensed health care provider, an allied-health professional, or a trained technician.

87. The method of claim 1 where TBW, ICW and/or ECW are measured by an end-user or consumer.

88. The method of claim 1 where TBW, ICW and/or ECW are measured in a medical office or facility, an allied-health office or facility, a spa, a fitness or wellness facility, or a pharmacy.

89. The method of claim 1 where TBW, ICW and/or ECW are measured in a retail store.

90. The method of claim 1 where TBW, ICW and/or ECW are measured at home.

3-23. -23. (canceled)

25-45. -45. (canceled)

47-49. -49. (canceled)

52-55. -55. (canceled)

57-59. -59. (canceled)

62-65. -65. (canceled)

70-71. -71. (canceled)

91. A method for increasing the phase angle in a person comprising administering therapeutically-effective amounts of an AAPP and at least one of an antioxidant, an anti-inflammatory agent, an essential fatty acid, a glycosaminoglycan, a trace mineral or a vitamin.

105. The method of claim 91 wherein the phase angle is increased by at least about 1%.

106. The method of claim 91 wherein the phase angle is increased by at least about 2%.

107. The method of claim 91 wherein the phase angle is increased by at least about 5%.

108. The method of claim 91 wherein the phase angle is increased by at least about 10%.

92-104. -104. (canceled)